Literature DB >> 1686208

Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene.

A N Nicholson1, P A Pascoe, C Turner, C R Ganellin, P M Greengrass, A F Casy, A D Mercer.   

Abstract

1. The effects of 10 mg (+)- and (-)-chlorpheniramine and 5 mg (+)- and (-)-dimethindene on daytime sleep latencies, digit symbol substitution and subjective assessments of mood and well-being were studied in 6 healthy young adult humans. Each subject also took 5 mg triprolidine hydrochloride as an active control and two placebos. 2. Daytime sleep latencies were reduced with triprolidine, (+)-chlorpheniramine and (-)-dimethindene, and subjects also reported that they felt more sleepy after (+)-chlorpheniramine and (-)-dimethindene. Performance on digit symbol substitution was impaired with (+)-chlorpheniramine. 3. Changes in measures with (-)-chlorpheniramine and (+)-dimethindene were not different from changes with placebo. 4. In the present study, changes in measures of drowsiness and performance were limited to the enantiomers with high affinity for the histamine H1-receptor. These findings strongly suggest that sedation can arise from H1-receptor antagonism alone, and provide further support for the belief that the histaminergic system is concerned with the regulation of alertness in man.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686208      PMCID: PMC1908262          DOI: 10.1111/j.1476-5381.1991.tb12418.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.

Authors:  D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

2.  Antiparkinsonian drugs and central dopamine neurons.

Authors:  K Fuxe; M Goldstein; A Ljungdahl
Journal:  Life Sci I       Date:  1970-07-15

Review 3.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

4.  [Behavior of chlorpheniramine in vivo after administration of d- and l-chlorpheniramine maleate].

Authors:  K Fujiwara; K Iwamoto; S Kawai; T Sakamoto
Journal:  Yakugaku Zasshi       Date:  1989-01       Impact factor: 0.302

5.  Peripheral antihistamine and central sedative effects of three H1-receptor antagonists.

Authors:  S Levander; O Hägermark; M Ståhle
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Comparative pharmacology of chlorpheniramine (Chlor-Trimeton) and its optical isomers.

Authors:  F E ROTH; W M GOVIER
Journal:  J Pharmacol Exp Ther       Date:  1958-12       Impact factor: 4.030

7.  Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay.

Authors:  N Kubo; O Shirakawa; T Kuno; C Tanaka
Journal:  Jpn J Pharmacol       Date:  1987-03

8.  Histaminergic systems and sleep. Studies in man with H1 and H2 antagonists.

Authors:  A N Nicholson; P A Pascoe; B M Stone
Journal:  Neuropharmacology       Date:  1985-03       Impact factor: 5.250

9.  Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system.

Authors:  E A Brown; R Griffiths; C A Harvey; D A Owen
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

10.  Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamine.

Authors:  H S Ahn; A Barnett
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

View more
  20 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Effects of the histamine H₁ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward.

Authors:  Erik B Oleson; Mark J Ferris; Rodrigo A España; Jill Harp; Sara R Jones
Journal:  Eur J Pharmacol       Date:  2012-03-15       Impact factor: 4.432

Review 4.  Dual-transmitter systems regulating arousal, attention, learning and memory.

Authors:  Sherie Ma; Balázs Hangya; Christopher S Leonard; William Wisden; Andrew L Gundlach
Journal:  Neurosci Biobehav Rev       Date:  2017-07-27       Impact factor: 8.989

5.  Effects of acrivastine, azelastine, cetirizine and noberastine on rat peritoneal mast cells.

Authors:  H Y Lau; C W Tsang; P P Wong
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

6.  Hypothalamic Tuberomammillary Nucleus Neurons: Electrophysiological Diversity and Essential Role in Arousal Stability.

Authors:  Akie Fujita; Patricia Bonnavion; Miryam H Wilson; Laura E Mickelsen; Julien Bloit; Luis de Lecea; Alexander C Jackson
Journal:  J Neurosci       Date:  2017-09-05       Impact factor: 6.167

7.  Histamine and Seizures : Implications for the Treatment of Epilepsy.

Authors:  H Yokoyama; K Iinuma
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

8.  Proconvulsive effects of histamine H1-antagonists on electrically-induced seizure in developing mice.

Authors:  H Yokoyama; K Onodera; K Iinuma; T Watanabe
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

10.  Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography.

Authors:  K Yanai; J H Ryu; T Watanabe; R Iwata; T Ido; Y Sawai; K Ito; M Itoh
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.